Therefore, in this study, four circulating angiogenic factors (CAFs), VEGF, FGF19, FGF23 and Ang-2, were chosen for further investigation of their suitability as predictive biomarkers of Lenvatinib treatment in patients with HCC. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.